It’s show-me time for batoclimab, an antibody treatment from Immunovant and Roivant Sciences. Here's what you need to know.

Management projected strong growth for 2025, driven by expanded reimbursement in key European markets such as Spain and Italy and the expected completion of the post-approval efficacy study (PAES).

UCB, a global biopharmaceutical company, today announced the CHMP (Committee for Medicinal Products for Human Use) has issued a positive opinion for the self-administration of RYSTIGGO® ...

"Slow Ride" singer Colt Ford described how he switched to a healthier lifestyle after he "died twice" from a near-fatal heart ...

Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations ...

Ford told PEOPLE he was diagnosed with myasthenia gravis in 2022, and was already in the process of losing weight, getting ...

Analyst Sam Slutsky of LifeSci Capital maintained a Buy rating on Immunovant (IMVT – Research Report), retaining the price target of ...

Colt Ford says his near-fatal heart attack last April helped kickstart a weight loss journey that's now trimmed him down by ...

Country-rap star Colt Ford got candid with People about his dramatic 60-pound weight loss following a near-fatal heart attack ...

Country-rap star Colt Ford got candid with People about his dramatic 60-pound weight loss following a near-fatal heart attack ...

Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

Welcome, ladies and gentlemen, to AstraZeneca's full-year and Q4 2024 results conference call for investors and analysts.